Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.
Press Enter ↵ to search evidence
Explore by Goal
"Science is the acceptance of what works and the rejection of what does not. That needs more courage than we might think."
- Jacob Bronowski
Quick Explanation
Copied
Battle-tested mechanism map (what the included data actually supports)
PARP family at DSBs: PARP1 and PARP2 can act very differently at DNA ends—single-molecule data show PARP2 forms stable end-bridges across 5′-phosphorylated blunt ends, while PARP1 binds ends but does not bridge under the same open-end conditions, and PARP1 can displace PARP2 bridges when ends are open.
PARP1 residency/repair-state modulation: Exosome-delivered YBX1-loaded Y RNA fragments increase PARP1 residency at DSBs and are linked to changes in PARP1 auto-modification and downstream DDR readouts in donor/recipient cell systems.
Pathway choice and resection-related effects: Multiple studies in this evidence set connect PARP activity and PARP inhibitor context to DSB end-processing and pathway shifts (e.g., PARP inhibitor–linked repair changes, and DSB cluster mutagenicity driven primarily by PARP1/alternative end-joining features).
Critical note: Your prompt references a specific “Amélie Rodrigue PARP1 resection DSB mechanism review,” but it is not present in the provided research dataset here, so I cannot validate, quote, or critique claims from that review directly.
Long Explanation
Best Evidence Battle-Test: “PARP1 resection / DSB mechanism”
I will only use what is present in the provided research data. The named target review (“Amélie Rodrigue…review”) is not included, so I assess the mechanism evidence from the supplied PARP1/DSB-related papers instead.
1) Visual evidence map (mechanism claims supported by which paper)
Node/edge semantics are evidence-linked; underlying claims are cited in the sections below.
2) Direct mechanistic constraints from the provided PARP1/2 biophysics
Key constraint:
In a PEG-constrained single-molecule geometry, PARP2 forms stable end-bridges across 5′-phosphorylated blunt ends, with bridging strength depending strongly on end chemistry, while PARP1 binds ends without bridging across the two ends under the same “open-end” condition; PARP1 can displace PARP2 bridging when ends are held apart.
PARP2 rupture-force peaks reflect bridging states (chemistry-dependent)
Values are taken from the provided extracted rupture-force summary for PARP2 bridging states.
3) PARP1 residency at DSBs: a pathway-modulating mechanism (not a guarantee of “resection”)
The provided evidence strongly supports that PARP1 residency/occupancy at DSBs can be modulated by non-coding Y RNA fragments delivered in a YBX1-dependent manner, linked to changes in DDR readouts and PARP1 auto-modification/residency timing.
Skeptical interpretation: “Higher PARP1 residency” is compatible with multiple causal paths (e.g., recruitment/docking platforms vs competition with other end-processing machineries). In the provided dataset, direct mechanistic linkage specifically to PARP1-mediated resection is not established by this paper alone.
4) DSB end-processing & pathway shift evidence that includes PARP1
4A) PARP inhibitors and repair pathway rewiring (context-dependent)
One provided study reports that Olaparib-mediated radiosensitization in a subset of tumor lines involves a switch toward a PARP1-dependent end-joining pathway (independent of homologous recombination in their experimental framing).
4B) DSB clusters: end resection + PARP1-linked alternative end-joining drives mutagenicity
In a human hHPRT forward mutation system, DSB clusters are far more mutagenic than single breaks, and mutagenicity increases with cluster complexity and PARP1 dependence. The provided extracted evidence also links ATM/CtIP (resection-enabling) to these mutagenic outcomes, while DNA-PKcs/c-NHEJ suppresses mutations more in simpler contexts.
Mutation frequency rises with DSB cluster size (reported single→cluster progression)
The extracted MF values are from the provided “list_of_extracted_data” summary for the CRISPR DSB cluster study.
5) How 53BP1-controlled resection control helps “resection vs residency” disentangling
A mechanistically crisp resection-pathway “choice” example in the provided dataset is a GSK3B→53BP1 axis: GSK3B phosphorylates 53BP1 at T334, reducing 53BP1 binding to PTIP/RIF1 and promoting end resection/HR markers (CtIP, RPA32, BRCA1, RAD51) while suppressing NHEJ. This matters because it gives a named resection-control mechanism with direct molecular endpoints that can be compared against any PARP1-resection hypothesis.
Critical battle-test question for PARP1 resection claims: If a PARP1–resection mechanism is real and central, then (within a given experimental context) PARP1 perturbation should produce resection-marker and pathway-choice shifts similar in direction and timing to canonical resection regulators (like the 53BP1/PTIP/RIF1 axis). The provided dataset here offers strong resection-axis evidence for 53BP1, but only residency/modulation evidence for PARP1 via YBX1/ysRNA.
6) Evidence-grade table: what is supported, what is uncertain
Mechanistic claim (battle-test target)
Best supporting evidence from provided dataset
Evidence strength
Uncertainties / what could falsify
PARP1 can bind DSB ends, but bridging competence differs from PARP2
PARP2 forms chemistry-dependent end bridges; PARP1 binds without bridging and can displace PARP2 under open-end conditions
Strong
In vitro geometry may not reflect chromatin; “no bridging” is context-dependent
PARP1 residency at DSBs is modulated by YBX1-loaded ysRNA
YBX1-dependent exosome/ysRNA biology increases PARP1 residency/occupancy at DSBs and correlates with DDR marker changes
Strong
Residency ≠ proved resection mechanism; resection biochemistry is not established in this excerpt
PARP1 activity contributes to mutagenic alt-EJ-like outcomes in complex DSB clusters where end resection is involved
PARP1 inhibition/deficiency nearly abolishes mutation frequency in DSB clusters; ATM/CtIP modulate end resection dependencies
Moderate
Single-locus model; CRISPR blunt-ended context may bias; PARP1 “resection” vs “repair-pathway engagement” still separable
PARP activity can influence repair choice indirectly through chromatin/DDR scaffolding (PARylation as docking/modulator)
Review describes PARylation as docking platform and modulator of DDR/chromatin and repair factor recruitment
7) Battle-tested “what would change my mind?” (disproof-oriented)
If “PARP1 resection” is claimed as primary: then PARP1 perturbation should change resection metrics (e.g., CtIP/RPA32/RAD51-loading shifts, resection tract length, end chemistry conversions) in a way that is not merely explained by PARP1 occupancy/residency differences. In this dataset, strongest direct resection-choice mechanistic endpoints come from the 53BP1/PTIP/RIF1 axis example, not from the PARP1 residency study.
PARP1 may be end-configuration dependent: single-molecule data show PARP1 lacks bridging competence in the tested open-end geometry and can displace PARP2 bridging; thus any “PARP1 bridges ends” claim needs context-specific support.
Pathway shifts ≠ “resection” per se: DSB cluster mutagenicity strongly depends on PARP1 and is resection/ATM/CtIP-related in the extracted evidence, but distinguishing whether PARP1 directly catalyzes resection vs acts downstream (repair pathway engagement, end processing choice, or alt-EJ support) requires direct resection tract assays in the same PARP1 perturbation regime.
8) Blind spots & common failure modes (epistemic humility)
Missing target review: Because the referenced “Amélie Rodrigue…review” is not included, I can’t confirm whether its claims align with (or contradict) the evidence summarized here.
Context switching: PARP1 functions appear highly dependent on end chemistry, geometry, chromatin context, and repair pathway context. The single-molecule and cell-based systems in the provided evidence differ substantially in complexity.
Over-aggregation risk: Reviews can be correct in aggregate while still being wrong about which mechanism is causally primary in a given biological setting. PARylation’s “docking platform” role is plausible, but ranking causality needs primary mechanistic assays.
Bottom line from the provided dataset: The evidence here most robustly supports (i) PARP1 vs PARP2 mechanistic divergence at end geometry (PARP1 no-bridge; PARP2 bridge under specific 5′P blunt-end chemistry), (ii) PARP1 residency at DSBs can be actively increased by YBX1-loaded ysRNAs, and (iii) PARP1-dependent alt/mutagenic outcomes in complex DSB clusters co-occur with ATM/CtIP-linked resection-enabling steps—yet direct “PARP1 catalyzes resection” causality is not proven by the provided excerpts alone.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
“PARP1 robustly bridges DSB ends like PARP2” is less favored given the provided single-molecule evidence where PARP1 does not bridge across ends under open-end conditions and can displace PARP2 bridges.
“PARP1 residency modulation by YBX1/ysRNA directly equals increased resection tract length” is not established by the provided summary; residency changes could occur without measurable tract-length increases.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Hypothesis Graveyard
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
